RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Laboratorios Farmaceuticos ROVI Stock

Laboratorios Farmaceuticos ROVI Debt 2024

Laboratorios Farmaceuticos ROVI Debt

40.11 EUR

Ticker

ROVI.MC

ISIN

ES0157261019

WKN

A0M0GQ

In 2024, Laboratorios Farmaceuticos ROVI's total debt was 40.11 EUR, a -175.95% change from the -52.81 EUR total debt recorded in the previous year.

Laboratorios Farmaceuticos ROVI Aktienanalyse

What does Laboratorios Farmaceuticos ROVI do?

Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Laboratorios Farmaceuticos ROVI's Debt Structure

Laboratorios Farmaceuticos ROVI's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Laboratorios Farmaceuticos ROVI's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Laboratorios Farmaceuticos ROVI’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Laboratorios Farmaceuticos ROVI’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

What is the debt of Laboratorios Farmaceuticos ROVI this year?

Laboratorios Farmaceuticos ROVI has a debt level of 40.11 EUR this year.

What was the debt of Laboratorios Farmaceuticos ROVI compared to the previous year?

The debt of Laboratorios Farmaceuticos ROVI has increased by -175.95% compared to the previous year dropped.

What are the consequences of high debt for investors in Laboratorios Farmaceuticos ROVI?

High debt can pose a risk for investors of Laboratorios Farmaceuticos ROVI, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Laboratorios Farmaceuticos ROVI?

Low debt means that Laboratorios Farmaceuticos ROVI has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Laboratorios Farmaceuticos ROVI affect the company?

An increase in debt of Laboratorios Farmaceuticos ROVI can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Laboratorios Farmaceuticos ROVI affect the company?

A reduction in debt of Laboratorios Farmaceuticos ROVI can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Laboratorios Farmaceuticos ROVI?

Some factors that can influence the debt of Laboratorios Farmaceuticos ROVI include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Laboratorios Farmaceuticos ROVI so important for investors?

The debts of Laboratorios Farmaceuticos ROVI are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Laboratorios Farmaceuticos ROVI take to change the debt?

To change the debt, Laboratorios Farmaceuticos ROVI can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Laboratorios Farmaceuticos ROVI pay?

Over the past 12 months, Laboratorios Farmaceuticos ROVI paid a dividend of 1.29 EUR . This corresponds to a dividend yield of about 1.76 %. For the coming 12 months, Laboratorios Farmaceuticos ROVI is expected to pay a dividend of 1.69 EUR.

What is the dividend yield of Laboratorios Farmaceuticos ROVI?

The current dividend yield of Laboratorios Farmaceuticos ROVI is 1.76 %.

When does Laboratorios Farmaceuticos ROVI pay dividends?

Laboratorios Farmaceuticos ROVI pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Laboratorios Farmaceuticos ROVI?

Laboratorios Farmaceuticos ROVI paid dividends every year for the past 21 years.

What is the dividend of Laboratorios Farmaceuticos ROVI?

For the upcoming 12 months, dividends amounting to 1.69 EUR are expected. This corresponds to a dividend yield of 2.3 %.

In which sector is Laboratorios Farmaceuticos ROVI located?

Laboratorios Farmaceuticos ROVI is assigned to the 'Health' sector.

Wann musste ich die Aktien von Laboratorios Farmaceuticos ROVI kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Laboratorios Farmaceuticos ROVI from 7/10/2024 amounting to 1.104 EUR, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did Laboratorios Farmaceuticos ROVI pay the last dividend?

The last dividend was paid out on 7/10/2024.

What was the dividend of Laboratorios Farmaceuticos ROVI in the year 2023?

In the year 2023, Laboratorios Farmaceuticos ROVI distributed 0.956 EUR as dividends.

In which currency does Laboratorios Farmaceuticos ROVI pay out the dividend?

The dividends of Laboratorios Farmaceuticos ROVI are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Laboratorios Farmaceuticos ROVI

Our stock analysis for Laboratorios Farmaceuticos ROVI Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Laboratorios Farmaceuticos ROVI Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.